Memory consolidation requires synaptic reconfiguration dependent upon extracellular matrix (ECM) molecules interacting with cell adhesion molecules. Matrix metalloproteinase (MMP) activity is responsible for transient alterations in the ECM that may be prerequisite to hippocampal-dependent learning. In support of this hypothesis we have measured increases in MMP-3 and MMP-9 levels within the hippocampus and prefrontal cortex during Morris water maze training. The present investigation extends these findings by determining that infusion of an MMP inhibitor (FN-439) into the dorsal hippocampus disrupted acquisition of this task. In vitro fluorescence enzyme assays to determine the specificity of FN-439 against the catalytic domains of MMP-3 and MMP-9 indicated mean +/- SEM IC(50)s of 16.2 +/- 7.8 and 210.5 +/- 37.8 muM, respectively, while in situ zymography using hippocampal sections treated with FN-439 indicated significant reductions in MMP gelatinase activity. These results suggest that compromising the ability of the dorsal hippocampus to reconfigure ECM molecules by inhibiting MMP activity interferes with appropriate spatial memory acquisition, and support a role for hippocampal MMPs in the phenomena of spatial memory acquisition and storage.
Memory consolidation requires synaptic reconfiguration dependent upon extracellular matrix (ECM) molecules interacting with cell adhesion molecules. Matrix metalloproteinase (MMP) activity is responsible for transient alterations in the ECM that may be prerequisite to hippocampal-dependent learning. In support of this hypothesis we have measured increases in MMP-3 and MMP-9 levels within the hippocampus and prefrontal cortex during Morris water maze training. The present investigation extends these findings by determining that infusion of an MMP inhibitor (FN-439) into the dorsal hippocampus disrupted acquisition of this task. In vitro fluorescence enzyme assays to determine the specificity of FN-439 against the catalytic domains of MMP-3 and MMP-9 indicated mean +/- SEM IC(50)s of 16.2 +/- 7.8 and 210.5 +/- 37.8 muM, respectively, while in situ zymography using hippocampal sections treated with FN-439 indicated significant reductions in MMP gelatinase activity. These results suggest that compromising the ability of the dorsal hippocampus to reconfigure ECM molecules by inhibiting MMP activity interferes with appropriate spatial memory acquisition, and support a role for hippocampal MMPs in the phenomena of spatial memory acquisition and storage.
Extracellular matrix (ECM) molecules mediate changes in the
brain's synaptic architecture thought to be critical to the
processes of neural plasticity, learning, and memory
[1-3]. The ECM is composed of secreted glycoproteins and
proteoglycans that form a network to which neurons and glia
adhere. The interaction among cells and the ECM is dependent upon
several types of cell adhesion molecules (CAMs) including
integrins, cadherins, and neural cell adhesion molecules
(see [4, 5] for reviews). ECM molecules make possible a wide range of signaling designed to influence
cellular proliferation, growth, movement, synaptic stabilization,
and apoptosis (see [6, 7] for reviews).Matrix metalloproteinases (MMPs) are a family of
proteinases important to the maintenance and restructuring of the
ECM [8-10]. MMPs modulate growth cone extension, neurite
development, synaptic transmission and long-term modification, and
neuronal degeneration [6, 11–14]. These processes
are essential to successful neural plasticity. MMP activity is
kept in check by tissue inhibitors of metalloproteinases
(TIMPs) that form tight noncovalent complexes with them, thus
preventing enzymatic activity [1, 15, 16]. MMP-9 is involved
in the remodeling accompanying kainic acid-induced epileptogenesis
[17, 18], and deafferentation-induced sprouting in
the dentate gyrus [19].The potential contribution of ECM remodeling to
learning and memory has only recently been addressed
[5, 6, 20–24]. Our laboratory has focused on hippocampal mediated spatial memory and measured elevations in hippocampal MMP-3 and MMP-9 during acquisition of the Morris water
maze task [25, 26]. The MMP inhibitor (MMPi) FN-439 interfered with the late-phase of long-term potentiation (LTP), and when infused intracerebroventricularly (icv) disrupted the
acquisition of the Morris water maze task [27].The present investigation further evaluated the potential role of
MMPs in spatial learning. The hippocampus has been shown to
mediate the acquisition of spatial memory [28-32], and the dorsal hippocampus is especially important in this regard [33, 34]. Thus, we bilaterally infused FN-439 into the
dorsal hippocampus in an attempt to disrupt performance on
the Morris water maze task over 8 days of training. Members of an
additional group of animals were icv infused with FN-439 for
comparison. The following specific questions were addressed. (1)
Can bilateral infusions of an MMPi into the dorsal hippocampus
block the acquisition of a spatial learning task? (2) Is the
magnitude of hippocampal MMPi-induced interference with the
acquisition of this task equivalent with that of icv delivered
MMPi? (3) How specific is FN-439 against MMP-3 and MMP-9?
2. EXPERIMENTAL PROCEDURES
2.1. Animals and surgical protocol
The protocols utilized in this investigation minimized pain and
discomfort, were approved by the Washington State University
Institutional Animal Care and Use Committee, and conformed to the
guidelines for the care and use of laboratory animals as required
by the National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 80-23). Male
Sprague-Dawley rats (300–350 g, breeding stock derived from
Taconic, Germantown, NY) were adapted to a 12-hour light/dark
cycle initiated at 0600 hour in the American Association for the
Accreditation of Laboratory Animal Care approved vivarium at a
temperature of 21 ± 1°C. The animals were housed in
pairs and provided with water and food (Harlan Teklad F6 Rodent
Diet, Madison, WI) ad libitum except the night prior to surgery
when food was withheld. Each animal was prepared with bilateral
guide cannulas targeting either the dorsal hippocampi (flat skull
coordinates relative to bregma: post: −4.0 mm, lat: ±2.5 mm from midline) or lateral ventricles (post: 1.0 mm,
lat: ±1.5 mm from midline) under ketamine-xylazine
anesthesia (100 and 2 mg/kg, resp., intramuscularly). The guide
was constructed from PE-60 tubing (Clay Adams, Parsippany, NJ)
with a heat bulge that rested on top of the cranium thus serving
as a stop to further penetration. The total length of the guide
was 2.5 cm with a distance from the beveled tip to the heat
bulge of 2.0 and 2.5 mm for the dorsal hippocampus and icv,
respectively. All infusions were made using a 30-gauge
stainless-steel tubing injector with a beveled end that protruded
2.0 mm beyond the tip of the PE guide cannula. The injector
was attached to a 10 μL Hamilton syringe by PE-20 tubing.
The animals were hand gentled for 5 minutes per day during the 7
days of recovery from surgery. Those animals prepared with dorsal
hippocampus guide cannulas were randomly assigned to one of two
groups (8 rats each) that received either FN-439 or artificial
cerebrospinal fluid vehicle (aCSF; in mM: 124 NaCl, 3
KCl, 1.24 KH, 1.3 MgSO, 2.0
CaCl, 26 NaHCO, and 10 D-glucose). Those animals prepared with icv cannulas were similarly assigned.
2.2. MMP inhibitor
Reeves et al. [19] determined that a 7.2 mM stock of
FN-439 (4-Abz-Gly-Pro-D-Leu-D-Ala-OH,
mw = 490.6; MMP inhibitor 1 #444250, Calbiochem, San Diego,
Calif) in aCSF infused over 30 minutes to a total volume of
100 μL (350 μg), inhibited MMP-9 activity by
83.6% as compared with aCSF infused control animals. Our
laboratory [27] previously used a 7.2 mM stock in aCSF icv infused over 5 minutes to a total volume of 10 μL
(35 μg) 10 minutes prior to behavioral testing, and again
3 hours post-testing (cumulative dose = 70 μg).
Presently, we utilized a 14.4 mM stock in aCSF infused over 1
minute to a total volume of 5 μL, that is, 2.5 μL for each side (17.5 μg in 2.5 μL aCSF/min) 20 minutes prior to behavioral testing (5 trials), and again 10 minutes after testing (cumulative dose = 70 μg) each day.
The protocol used for icv infusion was 35 μg in 5 μL aCSF infused over 1 minute, 20 minutes prior to testing and again 10 minutes following testing (cumulative dose = 70 μg). Behavioral testing in the Morris water maze task was conducted by an experimenter blind to the treatment of each animal.
2.3. Morris water maze task
The Morris water maze task [30] was used to test spatial memory acquisition. This protocol has been described in detail
[35]. Briefly, each trial entailed placing the animal into
the water facing the wall of the pool (1.6 m in diameter
painted black, filled to a depth of 30 cm) at one of four
locations (North (N), South (S), East (E), and West (W)) and
tracking its swimming path and duration (Chromatrac; San Diego
Instruments, San Diego, Calif) until the submerged platform was
found (12 cm in diameter painted black, 2 cm below the
surface). Swim speed was determined from these values. If the
animal located the platform within 120 seconds it was permitted 30
seconds on the platform before the next trial commenced. If the
animal did not find the platform it was placed on the platform and
allowed a 30-second rest period. The animal's entry point was
randomized on each trial, and the location of the platform was
randomly assigned to one of the four quadrants and remained fixed
for each animal throughout training (5 trials/day for 8 days). At
the conclusion of the 5 acquisition trials on day 8 each animal
was administered one probe trial. During this probe trial (120
seconds) the platform was removed and the time spent within the
target quadrant, and the number of crossings into the target
quadrant, were recorded.We also compared the groups concerning positive thigmotaxis on day
8 of training. Since the duration of each of the 5 trials on day 8
depended on how quickly the rat located the platform, the time
spent next to, or near (within 20 cm), the wall of the maze
was divided by total time of the trial. A ratio was determined for
each of the 5 trials and the mean of these five ratios was
calculated for each animal and submitted to one-way ANOVA.
2.4. Histological examination
Once behavioral testing was completed each animal
prepared with hippocampal cannulas was deeply anesthetized using
Equithesin (pentobarbital: 100 mg/kg, IP, Jensen-Salsbury
Labs, Kansas City, Mont) and transcardally perfused with
0.15 M NaCl followed by 10% formalin. Brains were removed and stored in a 30% sucrose in 10% formalin solution at
4°C for at least 7 days. Each brain was then horizontally
sectioned through the hippocampus (40 μm) using a
freezing microtome (Spencer Lens, Buffalo, NY). The sections were
mounted on gelatin-coated slides and stained with Cresyl violet.
The slides were cover-slipped and viewed using an overhead slide
projector (Model X-1000, Ken-A-Vision, Raytown, Mont), thus
permitting localization of the guide cannula and injector tracts
using Paxinos and Watson's atlas [36]. The location of the tip of the injector ranged from −3.6 to −4.5 mm posterior
to bregma, lateral 2.2 to 3.0 mm, and ventral to the surface
of cortex 2.2–2.8 mm.Those animals prepared with icv cannulas were anesthetized and
injected with 5 μL of fast green dye. The brain was
extracted and ventricles were checked for dye. All cannulas were
appropriately placed.
2.5. MMP enzyme assay
Enzyme assays for MMP activity were conducted in black 96-well
plates according to manufacturer instructions (Biomol
International LP, Plymouth Meeting, Pa). Catalytic domains for
MMP-3 and -9 were used with the fluorogenic peptide substrate:
Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH.
Solutions were preincubated with FN-439 for 30 minutes at
37°C. Subsequently, the fluorogenic peptide substrate was
added and fluorescence was measured at 10-minute intervals for one
hour using a Perkin-Elmer plate reader. Slopes were derived from
the linear portion of the curves and background slopes were
subtracted from all samples. The slopes were normalized as percent
of enzyme activity compared with activity in the absence of
inhibitor. IC values were extrapolated using quadratic and sigmoidal curve fit programs for each sample and were
averaged.
2.6. In situ zymography
Naïve rats were euthanized by decapitation, their brains were
sectioned (10 μm) using a cryostat and the sections were
mounted on slides and stored at −80°C for no longer than
a week. These sections were warmed to room temperature for 10
minutes and preincubated for 3 hours in either PBS (pH 7.4
control) or 14.4 mM FN-439 in PBS at 37°C. The
control slides were then incubated for an additional hour with
DQ-gelatin-FITC (DQ, Molecular Probes, Eugene, Ore) and the
treated slides were incubated with DQ containing 14.4 mM
FN-439 for 1 additional hour. Following incubation, the slides
were washed in PBS, fixed with 4% paraformaldehyde in PBS, and
cover slipped using prolong antifade mounting medium containing
DAPI (Molecular Probes, Eugene, Ore). The slides were examined
using a Zeiss Axioplan 2I microscope using epifluorescent
illumination and appropriate filter sets for visualizing DQ (FITC)
and DAPI (UV) fluorescence. Images were captured at 100–200X
magnification using a Kodak DC290 digital camera and Photoshop
software (Adobe Systems Inc, San Jose, Calif).
2.7. Statistical analyses
The mean latencies and distances to find the platform and swim
speeds during each daily block of five trials in the water maze
were analyzed using Groups X Days ANOVAs, with repeated measures
on the second factor. One-way ANOVAs were utilized to test for
potential differences among the groups on days 1 and 8 of
acquisition, to compare levels of thigmotaxis (swimming near the
walls of the maze) on day 8 of training, and regarding time spent
within, and the number of crossings into, the target quadrant
during probe trials. All significant effects from ANOVA analyses
were further evaluated using Newman-Keuls post hoc tests with the
level of significance set at P < .05.
3. RESULTS
3.1. Morris water maze performance
Figure 1 presents the mean ± SEM latencies (panel
(a)) and distances swum (panel (b)) to find the submerged platform
for each group over the 8 days of acquisition training. These
groups were not different regarding latencies to find the platform
at the initiation of training on day 1 (F = 0.27, P > .10). However, the overall results from the 4 (groups) ×8 (days) ANOVA indicated that both groups treated with MMPi
evidenced impaired acquisition as compared with aCSF infused
groups (F, P < .05). There was also an expected days effect (F, P < .0001); however, the interaction was not significant (F, P > .10). Post hoc analyses of the days effect indicated that latencies on days 5–8 were less than those on days 1–3, and days 3 and 4 were less than days 1 and 2 of acquisition. There were group differences on day 8 of acquisition (F, P < .001). Those animals injected with MMPi into the dorsal hippocampus or icv required significantly longer search times than those that received aCSF into the hippocampus or icv (day 8 mean ± SEM latencies: 37.9 ± 8.4, 44.4 ± 10.7, 13.4 ± 1.0, and 14.3 ± 1.9 s, resp.).
Figure 1
Mean ± SEM group changes in latencies (a) and
distances (b) to locate the platform in the Morris water maze
during 8 acquisition days. Five trials were administered per day
with the location of the platform fixed during training for each
animal. Bilateral injections of an MMP inhibitor (MMPi: FN-439)
into dorsal hippocampi (Hipp) or intracerebroventricularly (icv)
significantly interfered with the acquisition of the task. In
contrast, bilateral injections of the vehicle, artificial
cerebrospinal fluid (aCSF), into dorsal hippocampi or icv did not
interfere with the acquisition of this task of spatial memory.
Those groups injected with MMPi revealed significantly longer
latencies to find the platform than the aCSF injected groups on
days 5–8 of acquisition. *P < .05.
One-way ANOVA indicated that the groups were not different on day
1 of acquisition regarding distances swum to find the platform
(F, P > .10; Figure 1(b)). The 4 (groups) ×8 (days) ANOVA revealed a groups effect (F, P < .05), a significant days effect (F, P < .0001), but no interaction (F, P > .10). Post-hoc analyses of the groups effect indicated that both groups given MMPi swam greater distances to find the platform than those injected with aCSF. Post hoc analyses of the days effect suggested that distances on days 4–8 were less than those of days 1 and 2. Finally, there were group differences on day 8 (F, P < .005). Those rats injected with MMPi into the hippocampus or icv swam significantly longer distances to find the platform than those
given aCSF into the hippocampus or icv (12.1 ± 2.9, 12.9 ±
2.7, 4.2 ± 0.5, and 5.8 ± 0.7 m, resp.).Those rats injected with aCSF displayed superior search strategies
as compared with members of both MMPi treated groups
(Figure 2). This was illustrated by group differences
in positive thigmotaxis, that is, swimming at or near the walls of
the maze (F, P < .001). Post hoc analyses indicated that those animals infused with MMPi into the
hippocampus (0.37 ± 0.09) or icv (0.45 ± 0.11) revealed
greater thigmotaxic tendencies than those animals infused with
aCSF into the hippocampus (0.17 ± 0.06) or icv (0.14 ±
0.05).
Figure 2
Representative examples of search patterns in the
Morris water maze during a 120-second trial on day 8 of
acquisition training by one member of each group. Latency (Lat)
and distance (Dist) to find the platform are provided for each
rat. Bilateral injection of MMPi into dorsal hippocampi (Hipp) or
icv resulted in impaired search patterns characterized by frequent
swimming near the walls of the maze (positive thigmotaxis). Those
animals injected with aCSF into dorsal hippocampi or icv displayed
superior search patterns culminating in short latencies and
distances to find the platform. Members of these groups did not
differ with respect to swim speeds which ranged from 0.30 to
0.32 m/s.
Results from probe trials conducted at the conclusion of
acquisition training on day 8 are presented in Figure 3, and indicated differences among the groups regarding time spent in the target quadrant (F, P < .001). Post hoc analyses indicated that those animals injected with aCSF into the hippocampus or icv (40.7 ± 2.2 and 47.1 ± 4.0 s, resp.) revealed significantly greater
time spent in the target quadrant than those rats treated with
MMPi into the hippocampus or icv (34.3 ± 2.7 and 28.4 ±
0.8 s, resp.). The group that received icv MMPi indicated
significantly less time in the target quadrant than the other
groups. There were no differences considering the number of
entries into the target quadrant (F, P > .10). Nor were there differences in overall swim speeds during the 8 days of training for those groups treated with MMPi into the
hippocampus or icv, and those injected with aCSF into the
hippocampus or icv (0.32 ± 0.02, 0.31 ± 0.02, 0.30 ±
0.02, and 0.31 ± 0.02 m/s, resp.).
Figure 3
Mean ± SEM time spent by members of each group in the target quadrant during one 120-second probe trial (platform removed) following acquisition
training on day 8 in the Morris water maze. Bilateral injection of
an MMPi into dorsal hippocampi or icv significantly reduced time
spent in the target quadrant as compared with bilateral injection
of aCSF. Those animals icv injected with MMPi revealed the least
time spent in the target quadrant (28.4 ± 0.8 seconds)
followed by those injected with MMPi into the dorsal hippocampi
(34.3 ± 2.7 seconds). Those groups injected with the aCSF
into the dorsal hippocampi or icv displayed significantly greater
spent time (40.7 ± 2.2 and 47.1 ± 4.0 s, resp.).
*P < .05.
3.2. MMP enzyme assay
The mean ± SEM IC values for MMP-3 and -9 were determined to be 16.2 ± 7.8 and 210.5 ± 37.8 μM, respectively, indicating high specificity against MMP-3
(stromelysin-1) and reasonably good specificity for MMP-9
(gelatinase B) (Figure 4). These IC values were the reverse of those reported by Odake et al. [37], that is, 30 μM against gelatinase and 150 μM against
stromelysin. There are at least two possible explanations for
these differences. First, Odake and colleagues used HSF
stromelysin and HG gelatinase as substrates, while we used MMP-3
(stromelyisin-1) and MMP-9 (gelatinase B). Second, we used only
the catalytic domains of MMP-3 and MMP-9.
Figure 4
Results from fluorescence enzyme assays to establish the specificity of FN-439
for the catalytic domains of MMP-3 and MMP-9. The slopes were
derived from the linear portion of the curves and background
slopes were subtracted from all samples. The slopes were
normalized as percent of enzyme activity compared with activity in
the absence of inhibitor. IC values were extrapolated using quadratic or sigmoidal curve fit programs for each sample
and averaged. The determined mean ± SEM IC for MMP-3 and MMP-9 were 16.2 ± 7.8 and 210.5 ± 37.8 μM.
3.3. In situ zymography
Figure 5 presents the results of incubating
hippocampal sections with PBS or 14.4 mM FN-439 on MMPs (green
fluorescence) in situ. A similar appearance of cell nuclei (blue
fluorescence) was noted comparing control (PBS) and FN-439 treated
sections, suggesting no cellular toxicity. The basal activity of
MMP-9 was significantly reduced following FN-439 treatment as
indicated by a lack of green fluorescence. These in situ results
suggest that FN-439 significantly inhibited MMP-2 and MMP-9 in the
hippocampus.
Figure 5
Representative in situ zymography results demonstrating
gelatinase activity by MMPs in the dentate gyrus in the presence
of (a) PBS (control condition) upper panels or (b) FN-439
(14.4 mM) lower panels. The equivalent blue fluorescence of
cell nuclei suggests no cellular toxicity. MMP-2 and MMP-9
activity, visualized as green fluorescence, was significantly
inhibited by FN-439 as evidenced by reductions in green
fluorescence.
4. DISCUSSION
The present investigation was designed to further evaluate the
ability of an MMP inhibitor to influence acquisition of a spatial
memory task. We were particularly interested in determining the
specificity of FN-439 and whether infusion of this inhibitor into
the dorsal hippocampus disrupted acquisition of a spatial memory
task. The in vitro fluorescence assay results demonstrated that
FN-439 had a maximal effect upon the MMP-3 catalytic domain and
good specificity for the MMP-9 catalytic domain. In situ
zymography further determined that FN-439 significantly reduced
MMP gelatinase activity in hippocampal sections as compared with
PBS controls. In a previous investigation Reeves et al. [19] used a significantly larger icv dose of FN-439 (350 μg)
than in the present study (70 μg), following unilateral
lesions of the entorhinal cortex resulting in “collateral
sprouting of the crossed temporodentate fiber pathway.” These
rats were shown to lack the ability to demonstrate LTP in the
sprouting pathway. This points to an important role for MMPs in
the process of synaptogenesis and the capacity to form LTP in the
deafferentation/sprouting model.Presently, FN-439 significantly interfered with the acquisition of
the Morris water maze task of spatial learning and was
equivalently effective whether infused into the dorsal hippocampus
or icv delivered. Group differences in rate of acquisition could
not be attributed to differences in swim speed. Although we have
not tested FN-439 for hippocampal penetrability, we have
previously shown that icv delivered radio labeled small peptides
influence c-fos expression in the hippocampus [38]. It is likely that this low molecular weight inhibitor is also capable of
penetrating the hippocampus and influencing signaling when icv
injected. There were group differences comparing probe trial
results with the aCSF infused groups revealing greater time spent
in the target quadrant than the MMPi treated groups. The degree of
persistence to enter and remain in the target quadrant has been
utilized as a measure of successful acquisition. Although we
presently noted MMPi-induced interference with appropriate
acquisition of this task a larger dose of this inhibitor would be
expected to have an even greater negative impact on performance.
Related to this, the daily infusion volume of 2.5 μL over
one minute into the dorsal hippocampus may have resulted in tissue
damage that could explain the decreased persistence of the group
given aCSF to stay in the target quadrant during probe trials as
compared with the group given icv aCSF.Nagy et al. [3], Meighan et al. [27], and the present investigation move this research area towards the establishment of
a causal relationship between changes in brain MMP expression and
learning. Nagy and colleagues reported that the treatment of
hippocampal slices with an MMP-2/9 inhibitor disrupted late-phase
LTP but did not affect early-phase LTP. Similar results were
obtained using MMP-9 null mutant mice. In agreement with a
previous paper from our laboratory [27] the present findings
suggest a link between inhibition of hippocampal MMP-3 and -9 and
significantly reduced ability to acquire a spatial memory task,
and establish an important role for changes in MMP-3 and -9
expression within the dorsal hippocampus in the mediation of
spatial memory formation. Thus, these results add further support
to earlier work indicating that ECM molecules are
intimately involved in the modulation of synaptic
remodeling and connectivity [10, 21, 24, 39–42].In summary, hippocampal MMP-3 and MMP-9 appear to be instrumental
in the activation and maintenance of the neural plasticity
presumed to underlie spatial learning and memory. In the context
of current models of memory encoding and consolidation [7], compromising the ability of the dorsal hippocampus to reconfigure
ECM molecules by interfering with MMP activity appears to prevent
appropriate memory acquisition, and in turn its ability to pass
the stored memory onto other locations (e.g., prefrontal cortex) for
long-term storage.
Authors: John W Wright; Eric S Murphy; Itoro E Elijah; Kelby L Holtfreter; Chris J Davis; Mikel L Olson; Kalyani Muhunthan; Joseph W Harding Journal: Brain Res Date: 2004-10-08 Impact factor: 3.252
Authors: Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski Journal: J Neurosci Date: 2010-11-17 Impact factor: 6.167